VIGONVITA-B (02630) announced its annual results for the period ended December 31, 2025. The company recorded revenue of 102 million yuan, representing a significant increase of 762.9% compared to the previous year. However, the loss attributable to the company's owners was 356 million yuan, widening by 68.3% year-on-year. The basic loss per share was 2.33 yuan.

During the fiscal year ending December 31, 2025, the company's operating revenue saw substantial growth compared to the prior year. This core growth was primarily driven by two factors. First, following its market approval in July 2025, the company's Class 1 new drug Anweida® (product code: TPN171), used for treating male erectile dysfunction, demonstrated significant market promotion and sales effectiveness, leading to rapid revenue growth. Second, the License-out project for the respiratory syncytial virus (RSV) infection indication of the VV116 dry suspension reached a milestone, resulting in the successful receipt of a milestone payment.